Applied BioCode Corporation (TPE:6598)
Taiwan · Delayed Price · Currency is TWD 27.85
+0.15 (0.54%)
Aug 26, 2026, 1:30 PM CST
Applied BioCode Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 666.54 | 475.2 | 343.07 | 395.17 | 390.3 | 319.96 | |
Revenue Growth | 68.40% | 38.52% | -13.18% | 1.25% | 21.98% | 7.00% |
Cost of Revenue | 251.5 | 214.31 | 139.07 | 126.43 | 156.13 | 130.6 |
Gross Profit | 415.04 | 260.89 | 204 | 268.74 | 234.17 | 189.37 |
Selling, General & Admin | 185.37 | 185.13 | 209.05 | 209.15 | 188.04 | 148.46 |
Research & Development | 292.78 | 298.59 | 272.62 | 246.01 | 238.37 | 205.85 |
Operating Expenses | 479.58 | 484.23 | 481.91 | 455.44 | 426.77 | 354.31 |
Operating Income | -64.54 | -223.33 | -277.91 | -186.7 | -192.6 | -164.94 |
Interest Expense | -3.1 | -1.59 | -1.43 | -2.17 | -2.78 | -2.87 |
Interest & Investment Income | 17.53 | 22.94 | 27.63 | 23.96 | 8.51 | 3.11 |
Currency Exchange Gain (Loss) | 0.71 | 0.71 | -2.35 | -0.31 | 1.22 | -0 |
Other Non Operating Income (Expenses) | 0.75 | 0.15 | 0.16 | 0.01 | 0.95 | -0.46 |
EBT Excluding Unusual Items | -48.65 | -201.12 | -253.9 | -165.21 | -184.71 | -165.17 |
Gain (Loss) on Sale of Assets | - | - | - | -0.92 | - | -0.01 |
Legal Settlements | - | - | -6.88 | - | - | - |
Pretax Income | -48.65 | -201.12 | -260.78 | -163.44 | -184.71 | -165.18 |
Income Tax Expense | 0.24 | 0.08 | 0.03 | 0.76 | 0.02 | 0.02 |
Net Income | -48.89 | -201.2 | -260.81 | -164.2 | -184.73 | -165.2 |
Net Income to Common | -48.89 | -201.2 | -260.81 | -164.2 | -184.73 | -165.2 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 102 | 103 | 91 | 82 | 82 | 82 |
Shares Outstanding (Diluted) | 102 | 103 | 91 | 82 | 82 | 82 |
Shares Change | 1.10% | 13.45% | 10.82% | 0.01% | 0.07% | 5.33% |
EPS (Basic) | -0.48 | -1.96 | -2.88 | -2.01 | -2.26 | -2.02 |
EPS (Diluted) | -0.48 | -1.96 | -2.88 | -2.01 | -2.26 | -2.02 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -93.38 | -235.46 | -215.12 | -211.48 | 123.73 | -167.29 |
Free Cash Flow Per Share | -0.91 | -2.29 | -2.37 | -2.59 | 1.51 | -2.05 |
Gross Margin | 62.27% | 54.90% | 59.46% | 68.01% | 60.00% | 59.18% |
Operating Margin | -9.68% | -47.00% | -81.01% | -47.25% | -49.35% | -51.55% |
Profit Margin | -7.33% | -42.34% | -76.02% | -41.55% | -47.33% | -51.63% |
Free Cash Flow Margin | -14.01% | -49.55% | -62.70% | -53.52% | 31.70% | -52.29% |
EBITDA | -24.83 | -181.18 | -231.33 | -139.2 | -151.85 | -128 |
EBITDA Margin | -3.72% | -38.13% | -67.43% | -35.23% | -38.91% | -40.01% |
D&A For EBITDA | 39.71 | 42.16 | 46.58 | 47.5 | 40.75 | 36.94 |
EBIT | -64.54 | -223.33 | -277.91 | -186.7 | -192.6 | -164.94 |
EBIT Margin | -9.68% | -47.00% | -81.01% | -47.25% | -49.35% | -51.55% |